{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:51:47Z","timestamp":1777679507816,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,12]]},"DOI":"10.7759\/cureus.105113","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:44:25Z","timestamp":1773333865000},"source":"Crossref","is-referenced-by-count":1,"title":["A Case of Constipation During Cobenfy Therapy and a Constipation Prevention Protocol"],"prefix":"10.7759","author":[{"given":"Evaristus C","family":"Ezema","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Meftah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bashir","family":"Aribisala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satwant","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Sultana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jude","family":"Beauchamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uchenna","family":"Ezenagu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thant","family":"Htet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tolu","family":"Olupona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.24.1253","article-title":"Xanomeline-trospium (Cobenfy(TM)) for schizophrenia: a review of the literature","volume":"23","author":"Smith CM","year":"2025","unstructured":"Smith CM, Augustine MS, Dorrough J, Szabo ST, Shadaram S, Hoffman EO, Muzyk A. Xanomeline-trospium (Cobenfy(TM)) for schizophrenia: a review of the literature. Clin Psychopharmacol Neurosci. 2025, 23:2-14. 10.9758\/cpn.24.1253","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn M","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al.. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019, 394:939-51. 10.1016\/S0140-6736(19)31135-3","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/0706743717718167","article-title":"Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis","volume":"62","author":"Siskind D","year":"2017","unstructured":"Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry. 2017, 62:772-7. 10.1177\/0706743717718167","journal-title":"Can J Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.21101083","article-title":"Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia","volume":"179","author":"Paul SM","year":"2022","unstructured":"Paul SM, Yohn SE, Popiolek M, Miller AC, Felder CC. Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia. Am J Psychiatry. 2022, 179:611-27. 10.1176\/appi.ajp.21101083","journal-title":"Am J Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2009.07.024","article-title":"Evaluation of amphetamine-induced hyperlocomotion and catalepsy following long-acting risperidone administration in rats","volume":"620","author":"Marchese G","year":"2009","unstructured":"Marchese G, Casu G, Casti P, Spada GP, Pani L. Evaluation of amphetamine-induced hyperlocomotion and catalepsy following long-acting risperidone administration in rats. Eur J Pharmacol. 2009, 620:36-41. 10.1016\/j.ejphar.2009.07.024","journal-title":"Eur J Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan SK","year":"2021","unstructured":"Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021, 384:717-26. 10.1056\/NEJMoa2017015","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2003.tb00247.x","article-title":"Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists","volume":"9","author":"Mirza NR","year":"2003","unstructured":"Mirza NR, Peters D, Sparks RG. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev. 2003, 9:159-86. 10.1111\/j.1527-3458.2003.tb00247.x","journal-title":"CNS Drug Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1021\/cn400086m","article-title":"Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits","volume":"4","author":"Davie BJ","year":"2013","unstructured":"Davie BJ, Christopoulos A, Scammells PJ. Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits. ACS Chem Neurosci. 2013, 4:1026-48. 10.1021\/cn400086m","journal-title":"ACS Chem Neurosci"},{"key":"ref9","unstructured":"Food and Drug Administration. FDA approves drug with new mechanism of action for treatment of schizophrenia. (2024). Accessed. February 13, 2026: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-drug-new-mechanism-action-treatment-schizophrenia."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2013.00055","article-title":"Cholinergic connectivity: it's implications for psychiatric disorders","volume":"7","author":"Scarr E","year":"2013","unstructured":"Scarr E, Gibbons AS, Neo J, Udawela M, Dean B. Cholinergic connectivity: it's implications for psychiatric disorders. Front Cell Neurosci. 2013, 7:55. 10.3389\/fncel.2013.00055","journal-title":"Front Cell Neurosci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08050769","article-title":"Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry","volume":"165","author":"Lieberman JA","year":"2008","unstructured":"Lieberman JA, Javitch JA, Moore H. Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. Am J Psychiatry. 2008, 165:931-6. 10.1176\/appi.ajp.2008.08050769","journal-title":"Am J Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2022.09.006","article-title":"Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic","volume":"43","author":"Yohn SE","year":"2022","unstructured":"Yohn SE, Weiden PJ, Felder CC, Stahl SM. Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic. Trends Pharmacol Sci. 2022, 43:1098-112. 10.1016\/j.tips.2022.09.006","journal-title":"Trends Pharmacol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.112989","article-title":"Muscarinic M1 and M4 receptors: hypothesis driven drug development for schizophrenia","volume":"288","author":"Dean B","year":"2020","unstructured":"Dean B, Scarr E. Muscarinic M1 and M4 receptors: hypothesis driven drug development for schizophrenia. Psychiatry Res. 2020, 288:112989. 10.1016\/j.psychres.2020.112989","journal-title":"Psychiatry Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-clinpsy-050212-185538","article-title":"Emotion deficits in people with schizophrenia","volume":"9","author":"Kring AM","year":"2013","unstructured":"Kring AM, Elis O. Emotion deficits in people with schizophrenia. Annu Rev Clin Psychol. 2013, 9:409-33. 10.1146\/annurev-clinpsy-050212-185538","journal-title":"Annu Rev Clin Psychol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(84)90088-2","article-title":"A10 dopamine neurons: role of autoreceptors in determining firing rate and sensitivity to dopamine agonists","volume":"34","author":"White FJ","year":"1984","unstructured":"White FJ, Wang RY. A10 dopamine neurons: role of autoreceptors in determining firing rate and sensitivity to dopamine agonists. Life Sci. 1984, 34:1161-70. 10.1016\/0024-3205(84)90088-2","journal-title":"Life Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.71131","article-title":"Cobenfy (xanomeline-trospium chloride): a new frontier in schizophrenia management","volume":"16","author":"Hasan AH","year":"2024","unstructured":"Hasan AH, Abid MA. Cobenfy (xanomeline-trospium chloride): a new frontier in schizophrenia management. Cureus. 2024, 16:e71131. 10.7759\/cureus.71131","journal-title":"Cureus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2018.07.003","article-title":"The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: a positron emission tomography study","volume":"85","author":"Jauhar S","year":"2019","unstructured":"Jauhar S, Veronese M, Nour MM, et al.. The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: a positron emission tomography study. Biol Psychiatry. 2019, 85:79-87. 10.1016\/j.biopsych.2018.07.003","journal-title":"Biol Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-024-00525-6","article-title":"Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials","volume":"10","author":"Kaul I","year":"2024","unstructured":"Kaul I, Sawchak S, Claxton A, et al.. Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials. Schizophrenia (Heidelb). 2024, 10:102. 10.1038\/s41537-024-00525-6","journal-title":"Schizophrenia (Heidelb)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/med4.70013","article-title":"Xanomeline\u2010trospium chloride (Cobenfy): a new era in managing schizophrenia\u2014comparative effectiveness and economic challenges","volume":"3","author":"Hussain JM","year":"2025","unstructured":"Hussain JM, Arif W, Humayun S, Shoaib N, Khan SM. Xanomeline\u2010trospium chloride (Cobenfy): a new era in managing schizophrenia\u2014comparative effectiveness and economic challenges. Med Avd. 2025, 3:116-21. 10.1002\/med4.70013","journal-title":"Med Avd"},{"key":"ref20","unstructured":"Food and Drug Administration. FDA strengthens warning that untreated constipation caused by schizophrenia medicine clozapine (Clozaril) can lead to serious bowel problems. (2024). Accessed. February 13, 2026: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-strengthens-warning-untreated-constipation-caused-schizoph...."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/468671-a-case-of-constipation-during-cobenfy-therapy-and-a-constipation-prevention-protocol","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:44:28Z","timestamp":1773333868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/468671-a-case-of-constipation-during-cobenfy-therapy-and-a-constipation-prevention-protocol"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.105113","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}